On Thursday, BMO Capital Markets adjusted its price target on shares of 4D Molecular Therapeutics (NASDAQ:FDMT), reducing it to $40 from $63, while continuing to recommend the stock as Outperform. The revision follows the release of Phase II extension cohort data for one of the company's therapies.
The company's recent data showed that 77% of patients were able to avoid injections after 24 weeks, which is considered a favorable outcome compared to investor expectations of approximately 70%.
The analyst noted that the results were influenced by the administration of a second supplemental injection at four weeks, which was a new approach by the company and not previously used in the February data release or in comparative data from competitors.
The analyst expressed surprise at the decision to administer a second injection to patients who were already at a healthier baseline and therefore easier to treat. This deviation from previous protocols raises questions about the direct comparability of the new data with past results from the company and its peers.
The firm is seeking further details on the company's rationale and future plans regarding the use of supplemental injections in treatment protocols. The price target adjustment reflects these recent developments and the need for clarification on the strategic direction of the treatment's administration.
Despite the reduced price target, BMO Capital Markets maintains its positive outlook on the stock, indicating a continued belief in the company's overall performance and market potential. The new price target of $40 represents BMO's adjusted expectations for the company's share value moving forward.
In other recent news, 4D Molecular Therapeutics disclosed promising interim results from its Phase 2 clinical trial of 4D-150, an eye treatment for wet age-related macular degeneration. The treatment was shown to be safe and well-tolerated, reducing the need for standard anti-VEGF injections and improving visual acuity. Patients in the higher dose arm experienced an average improvement of +4.2 ETDRS letters from baseline.
In addition, RBC Capital Markets reiterated its Outperform rating on the biotechnology company, emphasizing the potential for improved outcomes in the wet Age-related Macular Degeneration population. BMO Capital Markets Corp. maintained its "Outperform" rating but lowered its price target due to the FDA's requirement for a Phase III randomized trial for the company's cystic fibrosis therapy.
Meanwhile, Barclays (LON:BARC) Capital Inc. initiated coverage on the company with an "Overweight" rating, expressing confidence in the wetAMD program and its product candidate 4D-150.
These recent developments are particularly noteworthy considering the company's strong financial position, with approximately $600 million in cash and equivalents as of Q4 2023, enabling the company to sustain its R&D efforts into the first half of 2027.
The company is expected to announce further results from ongoing trials for both wet AMD (NASDAQ:AMD) and diabetic macular edema in the coming months. These updates provide investors with crucial insights into the company's progress and potential.
InvestingPro Insights
In light of BMO Capital Markets' recent price target adjustment for 4D Molecular Therapeutics, a closer look at the company's financial health and stock performance through InvestingPro data may offer additional context for investors. With a market capitalization of $941 million, FDMT's financial position shows that it holds more cash than debt on its balance sheet, providing some financial stability. However, the company's P/E Ratio stands at -7.6, reflecting expectations of negative earnings.
InvestingPro Tips suggest caution as the stock has taken a significant hit over the last week and has underperformed over the past month. Moreover, the company's gross profit margins are weak, and analysts do not anticipate profitability this year. Despite these challenges, FDMT's liquid assets exceed its short-term obligations, which could provide some cushion against financial headwinds.
Investors looking for a deeper dive into FDMT's financial metrics and stock performance can find more InvestingPro Tips by visiting https://www.investing.com/pro/FDMT. For those interested in a subscription, use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. There are 11 additional InvestingPro Tips available that could further inform investment decisions regarding 4D Molecular Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.